^
    Back
    Association details:
    Biomarker:BTK C481S
    Cancer:Mantle Cell Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    ScienceDirect
    Title:

    The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

    Published date:
    07/30/2021
    Excerpt:
    In further support, SRX3262 treatment led to an increase in apoptotic cell death in either JeKo-1 BTK-WT or Ibrutinib-resistant cells JeKo-1 BTK-C481S and Mino BTK-C481S (Figures 4E and 4F). In contrast, Ibrutinib failed to induce apoptosis at the same concentrations as SRX3262, up to 5 μM.
    DOI:
    10.1016/j.isci.2021.102931